CGEM

Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Wall Street analysts forecast CGEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEM is 28.60 USD with a low forecast of 23.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cullinan Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Cullinan Therapeutics Inc. EPS for the last quarter amounts to -0.86 USD, increased 22.86 % YoY.

Cullinan Therapeutics Inc (CGEM) has 111 emplpoyees as of December 15 2025.

Today CGEM has the market capitalization of 704.19M USD.